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Abstract
Background—The melanocortin (MC) system is composed of peptides that are cleaved from the
polypeptide precursor proopiomelanocortin (POMC). Recent pharmacologic and genetic evidence
suggests that MC receptor (MCR) signaling modulates neurobiologic responses to ethanol and
ethanol intake. Because ethanol decreases POMC mRNA levels, we determined if exposure to an
ethanol-containing diet (ED) would significantly reduce central immunoreactivity of the MC peptide
α-MSH in rats. We also determined if ethanol exposure would alter the immunoreactivity of agouti-
related protein (AgRP), an endogenous MCR antagonist.
Methods—Male Sprague–Dawley rats were given 18 days of access to normal rodent chow or a
control diet (CD), or short-term (4 days) or long-term (18 days) access to an ED. At the end of the
study, rats were perfused with 4% paraformaldehyde and their brains were sectioned into two sets
for processing with α-MSH or AgRP immunohistochemistry.
Results—Rats exposed to an ED showed significant reductions of central α-MSH immunoreactivity
relative to rats exposed to a control diet (CD) or normal rodent chow. Ethanol-induced reductions of
α-MSH immunoreactivity were site-specific and were noted in regions of the hypothalamus and
extended amygdala, as well as the paraventricular nucleus of the thalamus. Because there were no
differences in body weights or caloric intake between the CD and ED groups, reductions of α-MSH
immunoreactivity in ED-treated rats are best explained by ethanol exposure rather than altered energy
balance. No significant ethanol-induced alterations in hypothalamic AgRP immunoreactivity were
detected.
Conclusions—The present study shows that ethanol site specifically reduces α-MSH
immunoreactivity in rat brain. These observations, in tandem with recent pharmacologic and genetic
studies, suggest that the endogenous MC system modulates neurobiologic responses to ethanol. Thus,
compounds which target MCRs may prove to have therapeutic value in the treatment of excessive
ethanol consumption and/or the symptoms associated with ethanol withdrawal.
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The melanocortin mc system is composed of peptides that are cleaved from the polypeptide
precursor proopiomelanocortin (POMC). Central MC peptides are produced by neurons within
the hypothalamic arcuate nucleus and the medulla (Dores et al., 1986; Jacobowitz and
O’Donohue, 1978; O’Donohue and Dorsa, 1982), and include adrenocorticotropic hormone
(ACTH), α-melanocyte stimulating hormone (α-MSH), β-MSH, and γ-MSH (Hadley and
Haskell-Luevano, 1999). Because of lack of a critical dibasic site, β-MSH is not processed in
rodent brain (Pritchard et al., 2002). Agouti related-protein (AgRP), a neuropeptide produced
in the hypothalamus and co-secreted with neuropeptide Y (NPY) in the same synaptic
complexes as α-MSH, functions as a natural MC receptor (MCR) antagonist (Shutter et al.,
1997).
There are several observations, which suggest that the MC system is a prime candidate for
regulating neurobiologic responses to drugs of abuse and drug self-administration. For
example, α-MSH administered into the ventral tegmental area (VTA) increases dopamine and
DOPAC levels in the nucleus accumbens (NAc; Lindblom et al., 2001), and chronic central
infusion of the non-selective MCR agonist, melanotan II (MTII), increases dopamine D1
receptor binding in the NAc and dopamine D2 receptor binding in the VTA (Lindblom et al.,
2002a). Thus, α-MSH and MTII alter dopamine signaling in these regions. Chronic treatment
of a high dose of morphine decreases MC-4 receptor (MC4R) mRNA in the NAc, the
periaqueductal gray, and neostriatum (Alvaro et al., 1996), brain regions that modulate drug
reward, opiate tolerance, and psychomotor stimulation, respectively (Kalivas and Stewart,
1991; Koob and Bloom, 1988; Wise and Bozarth, 1987). On the other hand, chronic treatment
with low doses of morphine or cocaine increases MC4R receptor mRNA in the striatum and
NAc (Hsu et al., 2005). Consistent with a role in drug self-administration, central infusion of
an MCR agonist decreases the acquisition of heroin self-administration in rats (van Ree et al.,
1981).
Importantly, there is also accumulating evidence that MC neuropeptides modulate
neurobiologic responses to ethanol. First, α-MSH is expressed in brain regions implicated in
ethanol’s effects, including the striatum, NAc, VTA, amygdala, hippocampus, and
hypothalamus (Bloch et al., 1979; Dube et al., 1978; Jacobowitz and O’Donohue, 1978;
O’Donohue and Jacobowitz, 1980; O’Donohue et al., 1979; Yamazoe et al., 1984). Second,
rats selectively bred for high ethanol drinking (AA (Alko, Alcohol)) have low levels of MC-3
receptor (MC3R) in the shell of the NAc, but have high levels ofMC3R andMC4R in various
regions of the hypothalamus, when compared with low ethanol drinking rats (Lindblom et al.,
2002b). Third, central infusion of MTII significantly reduced voluntary ethanol drinking in
AA rats with an established history of ethanol intake (Ploj et al., 2002). Similarly, MTII-
induced reduction of ethanol consumption was shown to be receptor-mediated and not
associated with alterations of ethanol metabolism in C57BL/6J mice (Navarro et al., 2003).
More recently, ventricular infusion of a selective MC4R agonist significantly reduced ethanol
drinking, while ventricular infusion of the non-selective MCR antagonist AgRP-(83–132)
significantly increased ethanol drinking, by C57BL/6J mice (Navarro et al., 2005).
In light of the above observations, and the fact that ethanol has direct effects on central POMC
mRNA activity (Rasmussen et al., 1998, 2002; Scanlon et al., 1992a; Zhou et al., 2000), an
important question is whether ethanol exposure influences central MC neuropeptide content
and in which brain regions. To this end, the present study determined if short-term (4 day) and/
or long-term (18 day) exposure to an ethanol-containing diet would alter the immunoreactivity
of α-MSH in rat brain. Because AgRP is an endogenous MCR antagonist (Shutter et al.,
1997), and central infusion of AgRP increases ethanol drinking (Navarro et al., 2005), the
immunoreactivity of AgRP in rats following chronic exposure to ethanol was also assessed.
Here we show that exposure to an ethanol diet for 4 or 18 days significantly reduced α-MSH
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immunoreactivity in specific regions of the hypothalamus, thalamus, and extended amygdala
while having no effect on the immunoreactivity of AgRP in the hypothalamus.
MATERIALS AND METHODS
Subjects
Male Sprague–Dawley rats (Charles River, Raleigh, NC, USA) were obtained at 160–180 g
and were maintained at 22°C with a 12:12 light/dark cycle. All rats were individually housed
in plastic rat cages with free access to water and standard rodent chow (Teklad, Madison, WI)
in the vivarium facilities of the Department of Psychology (University of North Carolina). All
procedures used in the present study were in compliance with the National Institute of Health
guidelines, and all procedures were approved by the University of North Carolina Institutional
Animal Care and Use Committee (IACUC).
Ethanol and Control Diets
The diet was a lactalbumin/dextrose-based, nutritionally complete diet (Dyets, Inc., Bethlehem,
PA). Dextrose calories in the control diet (CD) were equated with ethanol calories in the ethanol
diet (ED). Rats were habituated to drinking CD in the absence of rodent chow for 2 days (with
the exception of the chow control group described below). During the study, all rats with ED
were first habituated with 2 days access to a 4.5% (w/v) ED, followed by access to a 7% (w/
v) ED for an additional 2 or 16 days. A modified pair-feeding design was used. To equate the
caloric intake between groups, the rats maintained on the CD were given a volume of diet
equivalent to the average volume consumed the previous day by the rats maintained on the ED.
This diet has been used successful to study withdrawal-induced anxiety-like behavior in rats
(Breese et al., 2004; Knapp et al., 2004; Overstreet et al., 2002, 2004). Rodent chow was
removed from each rat cage during diet access and rats had access to a second bottle containing
tap water at all times.
Following habituation, rats were distributed to 4 groups matched on body weight (n = 10/group)
so that each group had approximately the same average weight at the beginning of the study.
To control for potential effects of diet on the immunoreactivity of α-MSH or AgRP, one group
of rats was maintained on normal rodent chow (Chow) for the entire study. A second control
group received CD in place of rodent chow for the duration of the study. A third group was
given CD for 14 days, the 4.5% ED for 2 days, and the 7% ED for 2 days (group ED4). A
fourth group received the 4.5% ED for 2 days, followed by the 7% ED for 16 days (group
ED18). Rats that experienced a similar protocol (15 days of access to at 7% ED) achieved blood
ethanol concentrations ranging from 100 mg/dl after the first day of access to 200 mg/dl during
the 15th day of access (Overstreet et al., 2002). Throughout the study, diet intake and body
weight measures were recorded daily.
Perfusions, Brain Preparation, and Immunohistochemistry (IHC)
Immunohistochemistry procedures were based on those routinely used in our laboratory (Hayes
et al., 2005; Knapp et al., 1998; Thiele et al., 1996, 1997, 1998a,b, 2000). Immediately after
18 days of access to diet, rats were injected with pentobarbital (100 mg/kg) and were then
perfused within 10 minutes transcardially with 0.1 mM phosphate-buffered saline (PBS; pH
7.4) followed by 4% paraformaldehyde in phosphate buffer. Rats were perfused in pairs, and
the order that rats were perfused was counterbalanced by diet condition. Rats had access to
diet up to the time of perfusions to avoid ethanol withdrawal in the ED groups. All perfusions
were completed within a 5-hour window of time. The brains were collected and post-fixed in
paraformaldehyde for 24 hours at 4°C, at which point they were transferred to PBS. Rat brains
were cut using a vibratome into 40 μm sections that were then stored in PBS until the IHC
assay. Sections were evenly divided into two sets (every-other section) for processing with α-
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MSH or AgRP antibodies. After rinsing in fresh PBS 4 times (10 minutes each), tissue sections
were blocked in 10% rabbit serum (for α-MSH) or 10% goat serum (for AgRP) and 0.1% triton-
X-100 in PBS for 1 hour. Sections were then transferred to fresh PBS containing primary sheep
anti-α-MSH (Millipore, Billerica, MA; 1:10,000) or primary rabbit anti-AgRP (Phoenix
Pharmaceuticals, Inc., Burlingame, CA; 1:4,000) for 3 days at 4°C. As a control to determine
if staining required the presence of the primary antibodies, some sections were run through the
assay without primary antibody (α-MSH or AgRP). In each assay described below, tissue
processed without the primary antibody failed to show staining that was evident in tissue
processed with primary antibody. After the 3 days of incubation, the sections were rinsed 4
times and then processed with Vectastain Elite kits (Vector Labs) as per the manufacturer’s
instructions for standard ABC/HRP/diaminobenzidine-based immunohistochemistry. The
sections processed for α-MSH or AgRP were visualized by reacting the sections with a 3,3′-
diamino-benzidine tetrahydrochloride (DAB, Polysciences, Inc., Warrington, PA) reaction
solution containing 0.05% DAB, 0.005% cobalt, 0.007% nickel ammonium sulfate, and
0.006% hydrogen peroxide. All sections were mounted on glass slides, air-dried overnight, and
cover slipped for viewing.
Digital images of α-MSH and AgRP immunohistochemistry were obtained on a Nikon E400
microscope equipped with a Nikon Digital Sight DS-U1 digital camera run with Nikon-
provided software. For analysis, great care was taken to match sections through the same region
of brain and at the same level using anatomic landmarks with the aid of a rat stereotaxic atlas
(Paxinos and Watson, 1986). For cell counting, all visible cell bodies stained within the defined
brain region were counted manually by an experimenter blinded to group condition. Data from
each brain region in an animal were calculated by taking the average counts from 2 brain slices.
Data from each slice were calculated by taking the average counts from the left and right sides
of the brain at the specific brain region of interest. For non-cell body localization of the α-MSH
or AgRP in a given brain region, densitometric procedures were used to assess protein levels.
Flat-field corrected digital pictures (8-bit grayscale) were taken using the Digital Sight DS-U1
camera and density of staining was analyzed using Image J software (Image J, National Institute
of Health, Bethesda, MD) by calculating the percent of the total area examined that showed
signal (cell bodies and processes) relative to a subthreshold background. The size of the areas
that were analyzed was the same between animals and groups. The subthreshold level for the
images was set in such a way that any area without an experimenter defined level of staining
was given a value of zero. Anatomically matched pictures of the left and right sides of the brain
were used to produce an average density for each brain region from each slice. In all cases,
quantification of immunohistochemistry data was conducted by an experimenter that was
blinded to group identity.
Data Analyses
All data in this report are presented as mean ± SEM differences between groups were analyzed
using one-way analyses of variance (ANOVA) procedures. Because we expected that ethanol-
induced alterations of α-MSH would be site specific, separate ANOVAs were performed for
each brain region. When significant differences are found, post hoc analyses were conducted
using the Tukey’s HSD test. For one set of analyses, t-tests were used for planned comparisons




Because both α-MSH and AgRP have been implicated in the modulation of food intake and
body weight (Sainsbury et al., 2002), it was important to determine if there were body weight
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differences between the different treatment groups over the course of the experiment. A one-
way ANOVA performed on baseline body weight data collected the day before the initiation
of diet exposure failed to achieve statistical significance (F3, 36 = 0.009; p > 0.05), a result
verifying the similar body weights between the Chow (286.6 ± 6.5 g), CD (287.7 ± 5.7 g), ED4
(287.7 ± 4.4 g), and ED18 (287.5 ± 4.8 g) groups. A one-way ANOVA performed on body
weight data collected at the end of the study was significant (F3, 36 = 16.19; p < 0.001). In this
case, Tukey’s HSD post-hoc tests revealed that while the Chow group (396.5 ± 9.4 g) weighed
significantly more than the CD (344.8 ± 5.0 g), ED4 (339.9 ± 6.1 g), and ED18 (326.8 ± 9.1
g) groups, none of the diet treated groups differed significantly from one another. Furthermore,
as the pair-feeding procedure equated the volume of diet consumption between CD and ED
groups, and because the CD and ED were calorically equated, there were no differences in
caloric intake between groups given access to liquid diet. These observations reinforce the
conclusion the differences between CD- and ED-treated groups below are best explained by
the presence or absence of ethanol exposure rather than group differences in caloric intake or
body weight.
Immunoreactivity of α-MSH in Regions of the Hypothalamus After Ethanol Exposure
Arcuate Nucleus of the Hypothalamus (Arc)—Data representing the average
immunoreactivity of α-MSH in the Arc are presented in Fig. 1, and represented
photomicrographs of α-MSH immunoreactivity in the Arc of groups CD and ED18 are depicted
in Fig. 2A and 2C (to conserve space, pictures of sections from the Chow and ED4 groups are
not presented in photomicrograph figures). The Arc was the only brain region in which α-MSH
was expressed in cell bodies rather than cellular processes. Thus, to verify that cell counting
and densitometric procedures yielded similar results, we quantified and analyzed α-MSH
immunoreactivity in this region using both procedures. Average cell counts of α-MSH-positive
cells in the Arc are presented in Fig. 1A. A one-way ANOVA performed on these data was
significant (F3, 36 = 36.28; p < 0.001). Tukey’s HSD post hoc tests revealed that both groups
ED4 and ED18 showed significantly lower immunoreactivity of α-MSH relative to the control
groups (Chow and CD). Average densities (% area) of α-MSH immunoreactivity in the Arc
are presented in Fig. 1B. Similar to the cell counting data, a one-way ANOVA performed on
density data was significant (F3, 36 = 44.81; p < 0.001), and Tukey’s HSD tests showed that
groups ED4 and ED18 showed significantly lower immunoreactivity of α-MSH relative to
groups Chow and CD.
Lateral (LH), Dorsomedial (DMH), and Paraventricular (PVN) Nuclei of the
Hypothalamus—Data representing the average immunoreactivity of α-MSH in the LH,
DMH, and PVN are presented in Fig. 3, and representative photomicrographs of α-MSH
immunoreactivity in the LH of groups CD and ED18 are depicted in Fig. 2B and 2D. A one-
way ANOVA performed on average densities of α-MSH immunoreactivity in the LH was
significant (F3, 36 = 5.77; p < 0.05). Tukey’s HSD tests revealed that while group ED18 had
significantly lower α-MSH immunoreactivity relative to both control groups (Chow and CD),
group ED4 did not differ significantly from the control groups (Fig. 3A). One-way ANOVAs
performed on average densities of α-MSH immunoreactivity in the DMH (F3, 36 = 0.38; p >
0.05) and PVN (F3, 36 = 0.23; p > 0.05) both failed to achieve statistical significance (see Fig.
3B and C, respectively).
Immunoreactivity of α-MSH in the Extended Amygdala, Thalamus, and Periaqueductal Gray
After Ethanol Exposure
Central Nucleus of the Amygdala (CeA) and Bed Nucleus of the Stria Terminalis
(BNST)—Data representing the average immunoreactivity of α-MSH in the extended
amygdala regions CeA and BNST are presented in Fig. 4A and B, respectively, and
representative photomicrographs from groups CD and ED18 in these regions are presented in
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Fig. 5. A one-way ANOVA performed on the average densities of α-MSH immunoreactivity
in the CeA was significant (F3, 36 = 3.05; p < 0.05). Although Tukey’s HSD tests did not reveal
significant group differences, planned t-test comparisons indicated that while group ED18
showed significantly lower levels of α-MSH immunoreactivity relative to the control groups
(Chow and CD), group ED4 did not differ significantly from the control groups. A one-way
ANOVA performed on average densities of α-MSH immunoreactivity in the BNST was
significant (F3, 36 = 17.96; p < 0.001), and Tukey’s HSD tests revealed that both of the ethanol
diet groups (ED4 and ED18) showed significantly lower levels of α-MSH immunoreactivity
relative to the control groups (Chow and CD).
Paraventricular Nucleus of the Thalamus (PVT) and Periaqueductal Gray (PAG)
—Data representing the average immunoreactivity of α-MSH in the PVT and PAGare
presented in Fig. 4C and 4D, respectively, and representative photomicrographs from groups
CD and ED18 in the PVT are presented in Fig. 6. A one-way ANOVA performed on the average
densities of α-MSH immunoreactivity in the PVT was significant (F3, 36 = 16.14; p < 0.001)
and Tukey’s HSD tests showed that both groups ED4 and ED18 had significantly lower α-
MSH immunoreactivity relative to the control groups (Chow and CD). A one-way ANOVA
performed on the average densities of α-MSH immunoreactivity in the PAG failed to reach
statistical significance (F3, 36 = 0.32; p > 0.05).
Immunoreactivity of AgRP in the Arc After Ethanol Exposure
Data representing the average densities (% of area) of AgRP immunoreactivity in the Arc are
presented in Fig. 7, and representative photomicrographs from groups CD and ED18 in this
region are depicted in Fig. 8. A one-way ANOVA performed on these data failed to achieve
statistical significance (F3, 36 = 1.20; p > 0.05).
DISCUSSION
Here we show that Sprague–Dawley rats exposed to an ethanol containing diet exhibit
significant reductions of central α-MSH immunoreactivity relative to rats exposed to a control
diet or normal rodent chow. Ethanol-induced reductions of α-MSH immunoreactivity were
noted in regions of the hypothalamus (the Arc and LH) and extended amygdala (the CeA and
BNST) as well as the paraventricular nucleus of the thalamus (PVT). Regions that did not show
ethanol-induced alterations of α-MSH immunoreactivity were the DMH, PVN, and PAG. We
did not find quantifiable levels of α-MSH immunoreactivity in other brain regions. The
observation that ethanol exposure reduced α-MSH in some, but not all, brain regions indicates
that the effects of ethanol exposure on α-MSH immunoreactivity are brain-region specific. This
observation limits the likelihood that ethanol-induced reductions of α-MSH immunoreactivity
were secondary to any global effects of ethanol on brain morphology or cellular toxicity.
Importantly, because there were no differences at the end of the study in body weights between
the group that received the CD versus the groups that received ED, and because caloric intake
between diet groups were matched, reductions of α-MSH immunoreactivity in ED-treated
groups are best explained by ethanol exposure, rather than group differences in caloric intake
or body weight. As rats that experienced a similar protocol (15-days of access to at 7% ED)
achieved blood ethanol concentrations ranging from 100 mg/dl after the first day of access to
200 mg/dl during the 15th day of access (Overstreet et al., 2002), the effects of ethanol exposure
on α-MSH immunoreactivity are probably related to the central pharmacologic actions of this
drug. These observations extend an earlier finding of ED-induced reduction of α-MSH
immunoreactivity in the Arc and substantia nigra (Rainero et al., 1990). On the other hand,
neither 4 or 18 days of exposure to ED caused significant alterations of AgRP immunoreactivity
in the Arc. Given that we observed AgRP immunoreactivity in only one brain region, and in
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the absence of other measures (e.g., mRNA levels), it would be premature to conclude that
ethanol exposure does not influence AgRP immunoreactivity.
With the exception of the LH and the CeA, which showed reductions of α-MSH
immunoreactivity only after 18 days of exposure to the ED, all other regions that were affected
by ED had reduced α-MSH immunoreactivity with both short-term (4 days) and long-term (18
days) exposure to ethanol. This observation raises the interesting possibility that the reduction
of α-MSH immunoreactivity in the LH and CeA progresses with the development of ethanol
dependence over the course of continued ethanol exposure. Consistent with this idea, Sprague–
Dawley rats show increased withdrawal-induced anxiety-like behavior after 17-days of access
to a 7% ED (Knapp et al., 2004), but not after 5-days of access to a 7% ED (Overstreet et al.,
2005). On the other hand, reductions of α-MSH immunoreactivity in regions after only 4-days
of ED access may represent neurobiologic responses to ethanol prior to the development of
ethanol dependence.
With immunohistochemistry procedures, reduced α-MSH immunoreactivity in response to
ethanol exposure could indicate that ethanol inhibits normal α-MSH signaling via reduced
production of α-MSH and/or interference of the normal transport of α-MSH to the terminals.
Alternatively, ethanol-induced reduction of α-MSH immunoreactivity may reflect an
augmentation of α-MSH signaling via potentiated release and/or the inhibition of α-MSH re-
uptake into presynaptic terminals. While either option is possible, the observation that exposure
to ethanol inhibits POMC mRNA (Rasmussen et al., 2002; Scanlon et al., 1992b; Zhou et al.,
2000) leads us to speculate that chronic exposure to ethanol disrupts normal α-MSH synthesis
which ultimately depletes α-MSH immunoreactivity in the terminals of brain regions involved
with neurobiologic responses to ethanol. A mechanism for the effects of ethanol on POMC
mRNA may involve GABA signaling. Ethanol is a sedative drug that enhances GABAergic
transmission (Criswell and Breese, 2005; Weiner and Valenzuela, 2006). Because peripheral
administration of GABA agonists reduced POMC mRNA in the arcuate nucleus of Sprague–
Dawley rats (Garcia de Yebenes and Pelletier, 1994), it is likely that reduction of POMC mRNA
(and thus reduced α-MSH immunoreactivity) results from increased GABAergic transmission
in the presence of ethanol.
Central MC signaling modulates food intake and body weight (Shimizu et al., 2007). Site-
directed injection of a melanocortin receptor agonist into the PVN, DMH, LH, Arc, and CeA
have been shown to significantly reduce food intake in rats (Giraudo et al., 1998; Kim et al.,
2000), and ventricular infusion of the melanocortin receptor agonist MTII, significantly
elevated c-Fos immunoreactivity in the PVN and Arc (Thiele et al., 1998b). While there is
clear overlap of brain regions in which melanocortin signaling controls feeding with those
regions exhibiting ethanol-induced reductions of α-MSH immunoreactivity, the PVN and
DMH are critical sites in which α-MSH signaling modulates feeding, yet no effects of ethanol
exposure on α-MSH immunoreactivity in the PVN or DMH were noted in the present report.
This observation, and the fact that ethanol-induced reductions of α-MSH immunoreactivity
were not attributable to calories or body weight change, suggests that the α-MSH pathways
that modulate feeding/body weight and neurobiologic responses to ethanol are not identical.
It is of interest to consider the possible role(s) that α-MSH signaling plays in the modulation
of neurobiologic responses to ethanol. One possibility is that α-MSH signaling is part of a
mechanism that prevents excessive ethanol drinking. While we did not assess the effects of
ED exposure on voluntary ethanol drinking in the present study, there is abundant evidence
that chronic exposure to an ethanol-containing diet or ethanol vapor augments voluntary
ethanol drinking during periods of withdrawal (Becker and Lopez, 2004; Finn et al., 2007;
Schulteis et al., 1996; Valdez et al., 2002). Thus, down-regulation of α-MSH signaling
following chronic exposure to ethanol may leave rats vulnerable to excessive ethanol intake.
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Consistent with this hypothesis are the observations that MCR agonists attenuate ethanol
drinking in rats and mice (Navarro et al., 2003, 2005; Ploj et al., 2002), while blockade of the
MCR augments ethanol drinking in mice (Navarro et al., 2005). As pretreatment with MTII
blocked ethanol-induced decreases of Met-enkephalin-Arg6Phe7 (MEAP) immunoreactivity
in the ventral tegmental area of rats, it is possible that MCR agonism reduces ethanol intake
through actions on the opioid system (Ploj et al., 2002). More recently we found that site-
directed infusion of a selective MC4R antagonist into the NAc increased ethanol drinking in
Sprague–Dawley rats (Carvajal et al., 2007), a finding that suggests that endogenous α-MSH
may negatively modulate the rewarding properties of ethanol via MC4R signaling in the NAc.
It should be noted, however, that there is also evidence that MCR signaling enhances the
rewarding properties of cocaine and amphetamine (Cabeza de Vaca et al., 2002; Hsu et al.,
2005). Regardless, while the mechanisms by which MCR signaling modulates the consumption
of ethanol and other drugs of abuse are not completely understood, such mechanisms may
involve an interaction of α-MSH with the opioid system as mentioned above (Ploj et al.,
2002), and/or by α-MSH actions within the mesolimbic dopaminergic pathway (Lindblom et
al., 2001, 2002a).
Another possibility is the reduced α-MSH immunoreactivity following ethanol exposure
contributes to the anxiolytic effects of ethanol. In fact, there is a growing body of literature
showing that MCR agonists induce, while MCR antagonists inhibit, anxiety-like behaviors in
rodents (Chaki and Okuyama, 2005; Chaki et al., 2003, 2005; Kokare et al., 2005; Nozawa et
al., 2007; Shimazaki and Chaki, 2005). Consistent with this idea is a recent report showing
that the anxiolytic effect of an intraperitoneal ethanol injection was suppressed by central
infusion of α-MSH but enhanced by central infusion of a MC4R antagonist or antiserum against
α-MSH (Kokare et al., 2006). Thus, ethanol- induced reduction of α-MSH immunoreactivity
may be part of the mechanism by which ethanol induces anxiolytic effects. If in fact ethanol-
induced reduction of α-MSH immunoreactivity contributes to the anxiolytic effects of ethanol,
one would predict that acute ethanol exposure would induce rapid reductions of α-MSH
immunoreactivity in critical brain regions as the anxiolytic effects of ethanol are immediate.
Furthermore, α-MSH immunoreactivity would be expected to return to normal levels soon after
ethanol is eliminated from the blood. These are important questions that will be the focus of
future research. Taken together, MCR signaling may modulate any number of neurobiologic
responses to ethanol, including ethanol ingestion, the rewarding properties of ethanol, and/or
ethanol’s anxiolytic properties. It will be important to determine the specific brain regions in
which α-MSH modulates these different neurobiologic responses.
In conclusion, here we show that chronic exposure to an ethanol-containing diet leads to
significant reductions of α-MSH within specific brain regions. Reductions of α-MSH are not
related to group differences in body weight or caloric intake. Future research is needed to
determine the precise mechanism by which ethanol modulates central α-MSH
immunoreactivity. The present observations, in tandem with recent genetic and pharmacologic
studies, strongly suggest that the endogenous MC system modulates neurobiologic responses
to ethanol. Thus, compounds which target MCRs may prove to have therapeutic value in the
treatment of excessive ethanol consumption and/or the symptoms associated with ethanol
withdrawal.
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Quantification of α-melanocyte-stimulating hormone (MSH) immunoreactivity in the arcuate
nucleus of the hypothalamus (Arc). Quantification was done by counting α-MSH-positive cell
bodies (A) or by measuring the density of α-MSH staining (B) using Image J software, which
calculated the percent of the total area examined (% area) that showed signal (cell bodies and
processes) relative to a subthreshold background. Groups were given 18-days of access to
normal rodent chow (Chow) or an ethanol-free control diet (CD), or an ethanol diet for 4 (ED4)
or 18 (ED18) days. Values are represented as mean ± SEM. There are statistical differences
between groups that do not share overlapping lettering (a or b; p < 0.05).
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Representative photomicrographs of 40 μm coronal sections showing α-melanocyte-
stimulating hormone (MSH) immunoreactivity through the arcuate nucleus of the
hypothalamus (A and C) and the lateral nucleus of the hypothalamus (B and D) of rats given
18 days of exposure to the control diet or the ethanol diet (Ethanol Diet 18). Dashed line depicts
the region that was selected for quantification. Images were photographed and quantified at a
magnification of 10×. Scale bar = 200 μm. α-MSH immunoreactivity in the arcuate nucleus
appears in cell bodies, while staining in the lateral hypothalamus is located primarily in cellular
processes.
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Quantification of α-melanocyte-stimulating hormone immunoreactivity (% area) in the lateral
nucleus of the hypothalamus (LH; A), the dorsomedial nucleus of the hypothalamus (DMH;
B), and the paraventricular nucleus of the hypothalamus (PVN; C). Groups were given 18 days
of access to normal rodent chow (Chow) or an ethanol-free control diet (CD), or an ethanol
diet for 4 (ED4) or 18 (ED18) days. Values are represented as mean ± SEM. There are statistical
differences between groups that do not share overlapping lettering (a or b; p < 0.05).
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Quantification of α-melanocyte-stimulating hormone immunoreactivity (% area) in the central
nucleus of the amygdala (CeA; A), the bed nucleus of the stria terminalis (BNST; B), the
paraventricular nucleus of the thalamus (PVT; C), and the periaqueductal gray (PAG; D).
Groups were given 18 days of access to normal rodent chow (Chow) or an ethanol-free control
diet (CD), or an ethanol diet for 4 (ED4) or 18 (ED18) days. Values are represented as mean
± SEM. There are statistical differences between groups that do not share overlapping lettering
(a or b; p < 0.05).
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Representative photomicrographs of 40 μm coronal sections showing α-melanocyte-
stimulating hormone (MSH) immunoreactivity through the central nucleus of the amygdala
(A and C) and the bed nucleus of the stria terminalis (B and D) of rats given 18 days of exposure
to the control diet or the ethanol diet (Ethanol Diet 18). Dashed line depicts the region that was
selected for quantification. Images were photographed and quantified at a magnification of
10×. Scale bar = 200 μm. α-MSH immunoreactivity in these regions is located primarily in
cellular processes.
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Representative photomicrographs of 40 μm coronal sections showing α-melanocyte-
stimulating hormone (MSH) immunoreactivity through the paraventricular nucleus of the
thalamus of rats given 18 days of exposure to the control diet (A) or the ethanol diet (B, Ethanol
Diet 18). Dashed line depicts the region that was selected for quantification. Images were
photographed and quantified at a magnification of 10×. Scale bar = 200 μm. α-MSH
immunoreactivity in this region is located primarily in cellular processes.
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Quantification of AgRP immunoreactivity (% area) in arcuate nucleus of the hypothalamus
(Arc). Groups were given 18 days of access to normal rodent chow (Chow) or an ethanol-free
control diet (CD), or an ethanol diet for 4 (ED4) or 18 (ED18) days. Values are represented as
mean ± SEM.
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Representative photomicrographs of 40 μm coronal sections showing AgRP immunoreactivity
through the arcuate nucleus of the hypothalamus of rats given 18 days of exposure ethanol diet
(Ethanol Diet 18; A) or to control diet (B). Dashed line depicts the region that was selected for
quantification. Images were photographed and quantified at a magnification of 10×. Scale bar
= 200 μm. AgRP immunoreactivity in this region is located primarily in cellular processes.
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